𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin's lymphoma

✍ Scribed by M. Quigley; M. Brada; C. Heron; Professor A. Horwich

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
789 KB
Volume
6
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

Nineteen patients in poor prognostic subgroups of aggressive non-Hodgkin's lymphoma (NHL) were treated with weekly chemotherapy consisting of low dose mitoxantrone and cyclophosphamide alternating with bleomycin and vincristine together with continuous oral prednisolone. Six patients developed pneumonitis which was severe in fivepatients. This occurred at total bleomycin doses of < 50 U/m2 and cyclophosphamide < 1875 mg/m2. The 31 per cent incidence of pneumonitis following low dose bleomycin suggests an increased susceptibility to drug-induced pulmonary damage in non-Hodgkin's lymphoma.

πŸ“œ SIMILAR VOLUMES

Etoposide, ifosfamide and methotrexate c
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-hodgkin's lymphoma after failure of the LNH 84 regimen
✍ R. Herbrecht; S. Ortiz; J. C. Damonte; K. L. Liu; F. Maloisel; P. Dufour; J. P. πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 353 KB

We assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 8

Effect of chemotherapy on resting energy
Effect of chemotherapy on resting energy expenditure in patients with non-Hodgkin's lymphoma results of a sequential study
✍ Jacques Delarue; Eric Lerebours; Herve Tilly; Agnes Rimbert; Patrick Hochain; Cl πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 464 KB πŸ‘ 3 views

This study compared the resting energy expenditure (REE) modifications observed during successive intensive identical chemotherapy courses in non-Hodgkin's lymphoma patients to assess indirectly the metabolic changes induced by the cytotoxic effect of drugs on the tumor. With this therapeutic regime

Second-line, low-dose, weekly paclitaxel
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
✍ Mark A. Socinski; Michael J. Schell; Kamal Bakri; Amy Peterman; Ji-Hyun Lee; Pau πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Second‐line chemotherapy with docetaxel improves survival and quality of life (QoL) in patients with nonsmall cell lung carcinoma (NSCLC) who fail first‐line platinum‐based regimens. The authors sought to determine the activity of second‐line, low‐dose, weekly paclitaxel

Complete regression of a suprasellar sec
Complete regression of a suprasellar secondary mass in a patient with low-grade non-Hodgkin's Lymphoma (NHL) Treated With 2-Chlorodeoxyadenosine (CDA)
✍ deCataldo, F.; Baudo, F.; Ottonelli, C.; Italia, C.; Valdagni, R. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 278 KB πŸ‘ 2 views

lymph node involvement with rt ureter compression that required a stent insertion. Brain CT showed a suprasellar lesion involving the diencephalic and chiasmatic regions (Fig. ). The patient was treated with CdA (2 hr-infusion of 0.14 mg/kg die Γ— 7 days) and Dexamethasone (0.3 mg/kg die Γ— 4 days). T

A randomized comparison of the efficacy
A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-hodgkin's lymphoma
✍ Reena Nair; Gopal Ramakrishnan; Narendran N. Nair; Tapan K. Saikia; Purvish M. P πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 3 views

## BACKGROUND. Combination chemotherapy consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin (MACOP-B) has been frequently used for the treatment of non-Hodgkin's lymphoma. This randomized study was undertaken to assess the efficacy and toxicity of th